SIRT1 and lung cancer: Accordingly, SIRT1 ISGylation promoted lung cancer progression and limited lung cancer cell sensitivity to DNA damage-based therapeutics in in vivo and in vitro models, and elevated expression of SIRT1 and ISG15 was associated with poor prognosis in lung cancer patients.